優創金融(01160.HK)供股獲認購約2.28%
格隆匯3月28日丨優創金融(01160.HK)公吿,於2022年3月10日下午四時正,公司已收到合共14份根據暫定配額通知書提呈的有效申請及接納,涉及合共197萬股供股股份,佔供股項下可供認購供股股份總數的約2.28%。
根據認購結果,供股中有8443萬股供股股份未獲認購,約佔供股項下可供認購供股股份總數的97.72%。
於2022年3月25日下午五時正,6250萬股未獲認購供股股份(佔緊隨供股完成後已發行股份的約26.34%)成功按每股配售價0.68港元配售予獨立承配人,較認購價溢價為零。
供股章程所載所有供股及配售的條件已獲達成,供股及配售於2022年3月25日下午五時正成為無條件。供股股份預期將於2022年3月30日上午九時正起按繳足股款形式於聯交所買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.